Fibroblast growth factor 21 predicts arteriovenous fistula functional patency loss and mortality in patients undergoing maintenance hemodialysis
AbstractBackground Arteriovenous fistula (AVF) dysfunction is a common complication in patients undergoing maintenance hemodialysis (MHD). Elevated serum levels of fibroblast growth factor 21 (FGF21) are associated with atherosclerosis and cardiovascular mortality. However, its association with vasc...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2024.2302407 |
| _version_ | 1797316682978426880 |
|---|---|
| author | Xinhui Hu Hong Ding Qing Wei Ruoxin Chen Weiting Zhao Liqiong Jiang Jing Wang Haifei Liu Jingyuan Cao Hong Liu Bin Wang |
| author_facet | Xinhui Hu Hong Ding Qing Wei Ruoxin Chen Weiting Zhao Liqiong Jiang Jing Wang Haifei Liu Jingyuan Cao Hong Liu Bin Wang |
| author_sort | Xinhui Hu |
| collection | DOAJ |
| description | AbstractBackground Arteriovenous fistula (AVF) dysfunction is a common complication in patients undergoing maintenance hemodialysis (MHD). Elevated serum levels of fibroblast growth factor 21 (FGF21) are associated with atherosclerosis and cardiovascular mortality. However, its association with vascular access outcomes remains elusive. The present study evaluated the relationship of serum FGF21 levels with AVF dysfunction and all-cause mortality in patients undergoing MHD.Methods We included patients undergoing MHD using AVF from January 2018 to December 2019. FGF21 concentration was detected using enzyme-linked immunosorbent assay. Patients were followed up to record two clinical outcomes, AVF functional patency loss and all-cause mortality. The follow-up period ended on April 30, 2022.Results Among 147 patients, the mean age was 58.49 ± 14.41 years, and the median serum level of FGF21 was 150.15 (70.57–318.01) pg/mL. During the median follow-up period of 40.83 months, the serum level of FGF21 was an independent risk factor for AVF functional patency loss (per 1 pg/mL increase, HR 1.002 [95% CI: 1.001–1.003, p = 0.003]). Patients with higher serum levels of FGF21 were more likely to suffer from all-cause mortality (per 1 pg/mL increase, HR 1.002 [95% CI: 1.000–1.003, p = 0.014]). The optimal cutoffs for FGF21 to predict AVF functional patency loss and all-cause mortality in patients undergoing MHD were 149.98 pg/mL and 146.43 pg/mL, with AUCs of 0.701 (95% CI: 0.606–0.796, p < 0.001) and 0.677 (95% CI: 0.595–0.752, p = 0.002), respectively.Conclusions Serum FGF21 levels were an independent risk factor and predictor for AVF functional patency loss and all-cause mortality in patients undergoing MHD. |
| first_indexed | 2024-03-08T03:22:52Z |
| format | Article |
| id | doaj.art-bc940fea3286477da465e2b329ffe313 |
| institution | Directory Open Access Journal |
| issn | 0886-022X 1525-6049 |
| language | English |
| last_indexed | 2024-03-08T03:22:52Z |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Renal Failure |
| spelling | doaj.art-bc940fea3286477da465e2b329ffe3132024-02-12T08:15:31ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492024-12-0146110.1080/0886022X.2024.2302407Fibroblast growth factor 21 predicts arteriovenous fistula functional patency loss and mortality in patients undergoing maintenance hemodialysisXinhui Hu0Hong Ding1Qing Wei2Ruoxin Chen3Weiting Zhao4Liqiong Jiang5Jing Wang6Haifei Liu7Jingyuan Cao8Hong Liu9Bin Wang10Institute of Nephrology, Zhong da Hospital, Southeast University School of Medicine, Nanjing, Jiangsu Province, ChinaInstitute of Nephrology, People’s Hospital of Yangzhong city, Zhenjiang, Jiangsu Province, ChinaInstitute of Nephrology, Zhong da Hospital, Southeast University School of Medicine, Nanjing, Jiangsu Province, ChinaInstitute of Nephrology, Zhong da Hospital, Southeast University School of Medicine, Nanjing, Jiangsu Province, ChinaInstitute of Nephrology, Zhong da Hospital, Southeast University School of Medicine, Nanjing, Jiangsu Province, ChinaInstitute of Nephrology, the Affiliated Suzhou Hospital of the Nanjing Medical University, Suzhou, Jiangsu Province, ChinaInstitute of Nephrology, Zhong da Hospital, Southeast University School of Medicine, Nanjing, Jiangsu Province, ChinaInstitute of Nephrology, Zhong da Hospital, Southeast University School of Medicine, Nanjing, Jiangsu Province, ChinaInstitute of Nephrology, the Affiliated Taizhou People’s Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, Jiangsu, ChinaInstitute of Nephrology, Zhong da Hospital, Southeast University School of Medicine, Nanjing, Jiangsu Province, ChinaInstitute of Nephrology, Zhong da Hospital, Southeast University School of Medicine, Nanjing, Jiangsu Province, ChinaAbstractBackground Arteriovenous fistula (AVF) dysfunction is a common complication in patients undergoing maintenance hemodialysis (MHD). Elevated serum levels of fibroblast growth factor 21 (FGF21) are associated with atherosclerosis and cardiovascular mortality. However, its association with vascular access outcomes remains elusive. The present study evaluated the relationship of serum FGF21 levels with AVF dysfunction and all-cause mortality in patients undergoing MHD.Methods We included patients undergoing MHD using AVF from January 2018 to December 2019. FGF21 concentration was detected using enzyme-linked immunosorbent assay. Patients were followed up to record two clinical outcomes, AVF functional patency loss and all-cause mortality. The follow-up period ended on April 30, 2022.Results Among 147 patients, the mean age was 58.49 ± 14.41 years, and the median serum level of FGF21 was 150.15 (70.57–318.01) pg/mL. During the median follow-up period of 40.83 months, the serum level of FGF21 was an independent risk factor for AVF functional patency loss (per 1 pg/mL increase, HR 1.002 [95% CI: 1.001–1.003, p = 0.003]). Patients with higher serum levels of FGF21 were more likely to suffer from all-cause mortality (per 1 pg/mL increase, HR 1.002 [95% CI: 1.000–1.003, p = 0.014]). The optimal cutoffs for FGF21 to predict AVF functional patency loss and all-cause mortality in patients undergoing MHD were 149.98 pg/mL and 146.43 pg/mL, with AUCs of 0.701 (95% CI: 0.606–0.796, p < 0.001) and 0.677 (95% CI: 0.595–0.752, p = 0.002), respectively.Conclusions Serum FGF21 levels were an independent risk factor and predictor for AVF functional patency loss and all-cause mortality in patients undergoing MHD.https://www.tandfonline.com/doi/10.1080/0886022X.2024.2302407Fibroblast growth factor 21hemodialysisarteriovenous fistulafunctional patencyall-cause mortality |
| spellingShingle | Xinhui Hu Hong Ding Qing Wei Ruoxin Chen Weiting Zhao Liqiong Jiang Jing Wang Haifei Liu Jingyuan Cao Hong Liu Bin Wang Fibroblast growth factor 21 predicts arteriovenous fistula functional patency loss and mortality in patients undergoing maintenance hemodialysis Renal Failure Fibroblast growth factor 21 hemodialysis arteriovenous fistula functional patency all-cause mortality |
| title | Fibroblast growth factor 21 predicts arteriovenous fistula functional patency loss and mortality in patients undergoing maintenance hemodialysis |
| title_full | Fibroblast growth factor 21 predicts arteriovenous fistula functional patency loss and mortality in patients undergoing maintenance hemodialysis |
| title_fullStr | Fibroblast growth factor 21 predicts arteriovenous fistula functional patency loss and mortality in patients undergoing maintenance hemodialysis |
| title_full_unstemmed | Fibroblast growth factor 21 predicts arteriovenous fistula functional patency loss and mortality in patients undergoing maintenance hemodialysis |
| title_short | Fibroblast growth factor 21 predicts arteriovenous fistula functional patency loss and mortality in patients undergoing maintenance hemodialysis |
| title_sort | fibroblast growth factor 21 predicts arteriovenous fistula functional patency loss and mortality in patients undergoing maintenance hemodialysis |
| topic | Fibroblast growth factor 21 hemodialysis arteriovenous fistula functional patency all-cause mortality |
| url | https://www.tandfonline.com/doi/10.1080/0886022X.2024.2302407 |
| work_keys_str_mv | AT xinhuihu fibroblastgrowthfactor21predictsarteriovenousfistulafunctionalpatencylossandmortalityinpatientsundergoingmaintenancehemodialysis AT hongding fibroblastgrowthfactor21predictsarteriovenousfistulafunctionalpatencylossandmortalityinpatientsundergoingmaintenancehemodialysis AT qingwei fibroblastgrowthfactor21predictsarteriovenousfistulafunctionalpatencylossandmortalityinpatientsundergoingmaintenancehemodialysis AT ruoxinchen fibroblastgrowthfactor21predictsarteriovenousfistulafunctionalpatencylossandmortalityinpatientsundergoingmaintenancehemodialysis AT weitingzhao fibroblastgrowthfactor21predictsarteriovenousfistulafunctionalpatencylossandmortalityinpatientsundergoingmaintenancehemodialysis AT liqiongjiang fibroblastgrowthfactor21predictsarteriovenousfistulafunctionalpatencylossandmortalityinpatientsundergoingmaintenancehemodialysis AT jingwang fibroblastgrowthfactor21predictsarteriovenousfistulafunctionalpatencylossandmortalityinpatientsundergoingmaintenancehemodialysis AT haifeiliu fibroblastgrowthfactor21predictsarteriovenousfistulafunctionalpatencylossandmortalityinpatientsundergoingmaintenancehemodialysis AT jingyuancao fibroblastgrowthfactor21predictsarteriovenousfistulafunctionalpatencylossandmortalityinpatientsundergoingmaintenancehemodialysis AT hongliu fibroblastgrowthfactor21predictsarteriovenousfistulafunctionalpatencylossandmortalityinpatientsundergoingmaintenancehemodialysis AT binwang fibroblastgrowthfactor21predictsarteriovenousfistulafunctionalpatencylossandmortalityinpatientsundergoingmaintenancehemodialysis |